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Objective: The aim of the study is to determine which clinic, radiologic, and surgical
characteristics of benign and atypical meningioma are associated with tumor progression.
Methods: 335 patients who underwent gross-total resection of intracranial benign and
atypical meningiomas between 2000 and 2009 were followed during the period of at least
3 years. Clinical, radiological and surgical features possibly associated with progression-free
survival and inﬂuencing tumor recurrence were assessed.
Results: 291 lesions were benign (WHO Grade I) and 44 were atypical (WHO Grade II). In the
median follow-up period of 82 months 34 meningiomas recurred. The 3-, 5- and 10-year
progression-free survival (PFS) rates for benign and atypical tumors were 99.7 and 81.4%, 97.5
and 69.7%, 87.5 and 69.7%, respectively. In a Kaplan–Meier analysis subpial plane of surgical
dissection (pial invasion) was associated with increased tumor progression both in benign
(p = 0.0084) and atypical cohort (p = 0.0104), and bone involvement (p = 0.0033) and peritu-
moral brain edema (p = 0.0073) were associated with increased tumor progression only in
atypical meningiomas. In a multivariate analysis pial invasion and WHO Grade II type were
signiﬁcantly associated with tumor recurrence. All recurrences in atypical meningioma
group occurred within 4 years of the surgical resection.
Conclusion: Pial invasion is an important predictor of tumor recurrence in benign and
atypical meningiomas. In atypical meningiomas bone involvement and large peritumoral
brain edema are associated with increased tumor progression.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnns1. Introduction
Meningiomas are usually slow-growing, well-circumscribed,
extra-axial tumors, and account for about 20% of all central* Corresponding author at: Klinika Neurochirurgii, Warszawski Uniwe
Tel.: +48 606 787 433; fax: +48 225 991 574.
E-mail address: arkady.n@wp.pl (A. Nowak).
http://dx.doi.org/10.1016/j.pjnns.2014.11.003
0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Unervous system neoplasms. Despite gross-total resection many
patients experienced tumor recurrence. Each recurrence carries
further risk of repeated surgery and much greater risk of
morbidity and mortality for the patient [1]. It has been well
established that the completeness of resection and histologicalrsytet Medyczny, ul. Banacha 1a, 02-097 Warszawa, Poland.
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The World Health Organization (WHO) grading system is helpful
for predicting aggressive meningioma subtypes. Although most
meningiomas are benign, approximately 10–40% demonstrate a
more aggressive clinical behavior and correspond to atypical
(Grade II) and anaplastic (Grade III) subtypes [2–4]. Among non-
benign lesion types, atypical meningiomas are most common,
however, there is limited information about them. According to
the 2000 and 2007 WHO tumor classiﬁcation [5], brain invasion
does not imply WHO Grade III meningioma. This revision of
diagnostic criteria was associated with increased incidence of
atypical meningiomas over the last decade [4]. Atypical
meningiomas show a heterogeneous treatment response in
contrast to anaplastic subtype which carry uniformly poor
prognosis. Some atypical meningiomas behave most like benign
subtype, others show slow progression from atypical to
anaplastic lesions or exhibit a precipitous decline [3]. Progres-
sion-free survival at 5 years after deﬁnitive treatment of atypical
meningiomas has been reported to be 38–62% [6–8]. However,
even benign meningiomas sometimes show relatively rapid
growth and may recur after total removal. Recurrence has been
estimated to occur in 9–15% of benign meningiomas after total
removal [9–11]. Preoperative identiﬁcation of high risk groups
for recurrence among benign and atypical subtypes would help
guide management and reduce treatment related toxicity.
Postoperative radiotherapy (RT) is used to reduce the probability
of recurrence, however, it remains unclear which benign and
atypical meningiomas will recur. Thus, we should try to identify
those patients who are at risk of recurrence and consider
adjuvant postoperative RT for these individuals.
The aim of the study is to determine which clinic,
radiologic, and surgical characteristics of benign and atypical
meningioma are associated with tumor progression and
analyze which prognostic factors are common and which
are divergent in the populations of benign and atypical
meningiomas.
2. Material and methods
2.1. Patient population
From 2000 to 2009, we operated on 463 patients with primary
intracranial meningiomas. We have retrospectively reviewed
the clinical records, neuroimaging studies, and follow-up data
of the treated patients. We included in the study patients with
the diagnosis of benign or atypical meningioma and no
multiple meningiomas or neuroﬁbromatosis who had under-
gone gross-total resection (GTR) and were observed for at least
3 years. The GTR designation included Simpson Grade I and
Grade II excisions [12], based on the surgeon's impression in
the operative report with postoperative conﬁrmation of
absence of residual tumor checked via MR imaging at the
3rd postoperative month. 46 of the 463 patients were excluded
because extent of resection was documented as subtotal
resection (STR) which included Simpson Grade III and IV
excisions. Twelve tumors represent malignant histological
type (WHO Grade III). Fifty four patients were excluded because
their follow-up period was less than 3 years. Sixteen of these
died perioperatively and 38 patients died of various diseaseswithin 3 years or were lost to follow-up. Sixteen patients had
neuroﬁbromatosis and/or were operated on for multiple
meningiomas. A total of 335 patients met the inclusion criteria
and were suitable for analysis.
2.2. Parameters assessed
Patient age at the initial surgery and patient gender were
recorded. According to their ages patients were classiﬁed into
two groups: patients younger than 60 years and patients of 60
years or older. All patients underwent Magnetic Resonance
Imaging (MRI) before surgery. Tumor locations were placed
into skull base and non-skull base. Tumor size was deﬁned by
the largest tumor diameter and categorized as large (≥4 cm) or
small (<4 cm). Tumor margins were described as smooth or
irregular. Calciﬁcation of the tumor was categorized as present
or absent and edema around the tumor was classiﬁed as small
and large according to Trittmacher criteria [13]. Surgical
ﬁnding included cleavage plane with pial-cortical invasion
present or absent. Bone changes were coded as present if they
were reported in operative or imaging reports. Among atypical
meningioma the use of postoperative adjuvant radiotherapy
(RT) was registered.
2.3. Patient's follow-up
Patients were examined in the outpatient clinic. The patient's
condition was assessed at follow-up based on neurological
examination and brain MRI in all of the patients. First
radiological examination performed 3 months after discharge
was mandatory. Then, each patient with atypical meningioma
underwent MRI every year. Postoperative MRI in cases of
benign tumor was obtained every 1 to 3 years.
Time to recurrence was calculated from the date of GTR to
the date of radiological evidence of tumor recurrence which
was determined with MRI. Patients underwent follow-up until
an endpoint of recurrence for progression-free survival (PFS)
analysis. In patients who did not experience progression
follow-up was censored at the last MRI study.
2.4. Statistical analysis
Tumor recurrence was analyzed against clinical and radiolog-
ical factors. Association between these variables was tested by
using Chi square and Fisher's exact tests. Risk for recurrence
with a conﬁdence interval of 95% (95% CI) was calculated for
each variable, and statistical signiﬁcance was determined for
p < 0.05. PFS rates were estimated using the Kaplan–Meier
method. Differences between survival curves were assessed by
the long-rank test. The prognostic inﬂuence of different factors
was determined by a multivariate analysis using the Cox's
proportional hazards model.
3. Results
3.1. Patient and tumor characteristics
Of the 335 patients in the study, 44 (13%) had atypical and 291
(87%) had benign meningiomas. There were 246 women
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 – 1 0 3(73.4%) and 89 men (26.6%) with a mean age at diagnosis of
57.9  11.3 years (range 18–85 years). There was no signiﬁcant
association between the WHO grade and sex or age at
diagnosis.
Patient and tumor characteristics are summarized in
Table 1.
In 39 (11.6%) cases cleavage plane of dissection was
predominantly subpial because of pia mater invasion. Intra-
operative evidence of bone involvement included hyperostosis
and bone destruction and was documented in 57 (17%)
patients. However, bone samples were not sent for histopath-
ological evaluation and hyperostosis or bone destruction were
usually drilled down to normal bone. WHO Grade II meningio-
mas were signiﬁcantly more often to exhibit pial invasion
(p = 0.0001), present large edema around the tumor (p = 0.001)
and surprisingly show higher tumor calciﬁcation rate
(p = 0.0047). Of the 44 atypical meningiomas in the series, 11Table 1 – Patient and tumor characteristics.
Factor Atypical
meningioma
(44 cases)
me
(2
Age (years)
Mean  SDa 57.4  10.5 58
Range 28–78 18
Median 58.5 58
95% CIb [54.2; 60.6] [56
Age (years)
<60 25 (56.8%) 15
≥60 19 (43.2%) 13
Sex
Female 28 (63.6%) 21
Male 16 (36.4%) 73
Tumor size (cm)
<4 cm 19 (43.2%) 13
≥4 cm 25 (56.8%) 16
Tumor location
Skull base 26 (59.1%) 16
Non-skull base 18 (40.9%) 12
Pial invasion
Present 17 (38.6%) 22
Absent 27 (61.4%) 26
Bone involvement
Present 12 (27.3%) 45
Absent 32 (72.7%) 24
Tumor margins
Regular 39 (88.6%) 27
Irregular 5 (11.4%) 19
Edema
Absent/mild 30 (68.2%) 25
Moderate/severe 14 (31.8%) 37
Tumor calciﬁcation
Present 7 (15.9%) 14
Absent 37 (84.1%) 27
Resection
Simpson Grade I 26 (59.1%) 17
Simpson Grade II 18 (40.9%) 11
Adjuvant radiotherapy
Yes 11 (25%) – 
No 33 (75%) – 
a Standard deviation.
b Confidence interval.(25%) received adjuvant postoperative radiotherapy in the
form of 3D conformal radiotherapy.
3.2. Recurrence rates
The median radiographic follow-up period for the entire cohort
was 82 months (mean 85  24.5 months, range 36–158 months).
Thirty four recurrences were detected during this time period.
There were no signiﬁcant differences in follow-up time between
the WHO Grade I and the WHO Grade II tumors (Table 2a). WHO
Grade II type was associated with a higher recurrence rate than
WHO Grade I type (p = 0.0001) (Table 2b). Moreover, the mean
time to progression was signiﬁcantly shorter among patients in
the WHO Grade II subgroup (p = 0.0001). The 3-, 5- and 10-year
progression-free survival (PFS) rates for WHO Grade I meningi-
omas were signiﬁcantly higher compared to atypical meningi-
omas (log-rank = 4.75, p = 0.0001) (Table 3, Fig. 1).Benign
ningioma
91 cases)
Total
(335 cases)
p-Value
.0  11.4 57.9  11.3 0.5936
–85 18–85
.0 58.0
.7; 59.3] [56.7; 59.1]
5 (53.3%) 180 (53.7%) 0.6595
6 (46.7%) 155 (46.3%)
8 (74.9%) 246 (73.4%) 0.1144
 (25.1%) 89 (26.6%)
0 (44.7%) 149 (44.5%) 0.8528
1 (55.3%) 186 (55.5%)
9 (58.1%) 195 (58.2%) 0.8987
2 (41.9%) 140 (41.8%)
 (7.6%) 39 (11.6%) 0.0001
9 (92.4%) 296 (88.4%)
 (15.5%) 57 (17.0%) 0.0520
6 (84.5%) 278 (83.0%)
2 (93.5%) 311 (92.8%) 0.2465
 (6.5%) 24 (7.2%)
4 (87.3%) 284 (84.8%) 0.0010
 (12.7%) 51 (15.2%)
 (4.8%) 21 (6.3%) 0.0047
7 (95.2%) 314 (93.7%)
8 (61.2%) 204 (60.9%) 0.7924
3 (38.8%) 131 (39.1%)
11 (3.3%) –
324 (96.7%)
Table 2a – Clinical follow-up.
Atypical
meningioma
(44 cases)
Benign
meningioma
(291 cases)
Total
(335 cases)
p-Value
Follow-up (months)
Mean  SD 81.9  24.9 85.5  24.4 85.0  24.5 0.4621
Range 36–135 42–158 36–158
Median 84.0 82.0 82.0
95% CI [74.3; 89.6] [82.6; 88.3] [82.4; 87.7]
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 – 1 043.3. Analysis of factors potentially related to progression-
free survival (Kaplan–Meier analysis using log-rank testing)
3.3.1. Benign meningiomas
Table 4 shows the correlation between clinical, radiographic
and intraoperative ﬁndings and progression-free survival
in benign and atypical meningiomas. Subpial surgical
cleavage plane (pial invasion) was associated with an
increased rate of progression compared to extrapial cleavage
plane of dissection (p = 0.0084) (Fig. 2). Tumor recurred in
5 of 22 (23%) patients with subpial surgical plane. In
contrast tumor progression was noted in 16 of 269 (6%)
cases of extrapial surgical plane. There was no signiﬁcant
association between tumor relapse and other variables
assessed.
3.3.2. Atypical meningiomas
Similarly to benign meningiomas in atypical tumors pial
invasion (tumor progression in 53% of cases) was also
associated with an increased rate of recurrence compared to
no evidence of pial invasion (p = 0.0104) (Fig. 3 and Table 4).
Furthermore, evidence of bone involvement (p = 0.0033) and
large peritumoral brain edema (p = 0.0073) were also associat-
ed with tumor relapse (Figs. 4 and 5). Tumor progression was
found in 7 of 12 (58%) cases with bone involvement and in 6 of
14 (43%) cases of large edema. On the other hand there was
evidence of meningioma recurrence in 6 of 32 (19%) cases
without evidence of bone involvement and 7 of 30 (23%) cases
with small edema.
One of the 14 (7%) patients who received immediate
postoperative radiotherapy experienced recurrence over the
follow-up period, compared to 12 of the 30 (40%) patients who
had not received radiotherapy. Using Kaplan–Meier analysis
with log-rank testing, these differences were not statistically
signiﬁcant (p = 0.079).Table 2b – Tumor recurrence.
Atypical
meningioma
(44 cases)
me
(2
Tumor recurrence 13 (29.6%) 21
Tumor recurrence (months)
Mean  SD 31.0  9.4 72
Range 16–47 32
Median 30.0 75
95% CI [25.3; 36.7] [613.4. Multivariate analysis of factors predicting tumor
recurrence
In a multivariate analysis pial invasion and WHO Grade II type
were signiﬁcantly associated with tumor recurrence (Table 5).
However, the Cox's regression model reached statistical
signiﬁcance only for the entire combined group of both
WHO Grade I and Grade II tumors, while separate statistical
models for benign and atypical meningiomas were not
statistically signiﬁcant. When a subpial plane of dissection
changes to an extrapial plane the hazard ratio (HR) is 0.26
( p = 0.0021). This means that change in plane of dissection
from subpial to extrapial causes a decrease in the risk of
recurrence. Similarly a change from atypical to benign tumor
decreases the risk of relapse (HR = 0.37; p = 0.0158).
4. Discussion
This retrospective analysis of prognostic indicators for recur-
rence from a single-institution case series of benign and
atypical meningioma revealed that subpial plane of surgical
dissection is associated with increased tumor progression
both in benign and atypical cohort. Furthermore bone
involvement and peritumoral brain edema were associated
with increased tumor progression in atypical meningiomas.
All recurrences in atypical meningioma group occurred within
4 years of the surgical resection.
The advantages of this series are the large number of cases,
relatively high length of radiographic and clinical follow-up
and direct comparison of the groups of benign and atypical
meningiomas.
There is a general agreement that completeness of surgical
resection and histological features (WHO classiﬁcation) are the
most important predictors of meningioma recurrenceBenign
ningioma
91 cases)
Total
(335 cases)
p-Value
 (7.2%) 34 (10.2%) 0.0001
.7  25.2 56.8  29.0 0.0001
–122 16–122
.0 47.0
.3; 84.2] [46.7; 66.9]
Table 3 – Progression-free survival rates in atypical and benign meningiomas.
Atypical
meningiomas
(44 cases)
Benign
meningiomas
(291 cases)
Total
(335 cases)
3-year progression-free survival rate 81.4% 99.7% 97.3%
5-year progression-free survival rate 69.7% 97.5% 93.9%
10-year progression-free survival rate 69.7% 87.5% 85.2%
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 – 1 0 5[7,12,14]. Dziuk et al. [6] reported that in patients with atypical
meningioma GTR was associated with lower recurrence rates
(17%) than STR (87%). Palma et al. [3] revealed that radical
resection (Simpson Grade I vs. Grades II–III) and histological
type (WHO Grade II vs. WHO Grade III) were signiﬁcantly
related to progression and survival. In the Mayo Clinic series
[15], estimated 5-year mortality rates in atypical and anaplas-
tic meningiomas were 25 and 83%, respectively. Adeberg et al.
[16] reported signiﬁcant impact of histological grade on overall
(81% for atypical and 53% for malignant meningioma at 5
years) and progression-free survival (50% for atypical and 13%
for malignant meningioma at 5 years).
Because of well-known beneﬁcial impact of GTRs on tumor
control and survival we sought to deﬁne other clinical and
radiologic features predicting recurrence of meningioma.
There is limited knowledge on clinical features associated
with progression especially in atypical meningiomas, which
represents an intermediated prognostic group between the
benign and malignant types. Furthermore, it was interesting to
ﬁnd out common factors that could affect tumor recurrence in
benign and atypical cases.
Many case series postulated other prognostic factors
associated with the meningioma recurrence rate but most of
them were not uniformly accepted. Several studies reportedFig. 1 – Kaplan–Meier progression-free survival curve of atypical v
significant difference between the groups favoring benign subtysigniﬁcant inﬂuence of male sex on recurrence [17–19]
although this has been not conﬁrmed by other studies
[10,20,21]. The explanation of this conﬂicting results is
probably the fact that in many series males more frequently
have atypical or anaplastic meningiomas [18,19] which are
associated with poorer prognosis. Mahmood et al. [18]
analyzed benign and malignant meningiomas separately
and then found that gender did not inﬂuence the recurrence
rate.
Perry et al. [19] reported increased rate of meningioma
recurrence in patients at a young age (<40 years) but most
studies found no signiﬁcant difference among patients who
have benign, atypical or anaplastic tumors [10,17,20]. However,
some new studies found that older age (>60 years) is
associated with unfavorable outcome [22–25] in series of
atypical and malignant meningioma.
Among radiologic ﬁndings associated with less favorable
outcome in patients operated on for meningioma are the
presence of marked surrounding edema, absence of calciﬁca-
tions and the presence of irregular tumor borders or
‘‘mushrooming’’. The presence of irregular tumor margins is
considered signiﬁcant prognostic factor for tumor recurrence
in that it could reﬂect high proliferative potential of meningi-
oma [20]. Our study does not conﬁrm this suspicion, both inersus benign meningioma. Log rank testing demonstrated a
pe (p = 0.0001).
Table 4 – Patient and tumor factors influencing progression-free survival.
Factor Variable Atypical
meningiomas
Benign
meningiomas
Total
Log-rank
test
p-Value Log-rank
test
p-Value Log-rank
test
p-Value
Sex Female vs. male 0.09 0.9247 1.26 0.2091 1.5 0.1344
Age (years) <60 vs. ≥60 0.48 0.6301 0.32 0.7456 0.57 0.5708
Tumor size <4 cm vs. ≥4 cm 0.12 0.9066 0.23 0.8155 0.29 0.7693
Tumor location Skull base vs. non-skull base 0.75 0.4554 0.72 0.4721 1.01 0.3125
Pial invasion Present vs. absent 2.56 0.0104 2.64 0.0084 5.57 0.0001
Bone invasion Present vs. absent 2.94 0.0033 1.06 0.2888 3.11 0.0019
Tumor margins Regular vs. irregular 0.55 0.5835 1.24 0.2138 1.60 0.1088
Edema Absent/mild vs. moderate/severe 2.68 0.0073 1.25 0.2127 1.31 0.1904
Calciﬁcation Present vs. absent 0.10 0.9233 0.06 0.9560 0.69 0.4871
Resection Simpson Grade I vs. Simpson
Grade II
0.49 0.6208 1.31 0.1900 1.39 0.1659
Radiotherapy Yes vs. no 1.76 0.0790 – – – –
Values in bold indicate statistical signiﬁcance.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 – 1 06benign and atypical meningioma. Similarly, we did not ﬁnd
association between lack of tumor calciﬁcation and tumoral
recurrence presence. Mantle et al. [26] demonstrated that the
peritumoral edema grade correlated with tumor recurrence
after complete resection. They found that brain invasion was
demonstrated in all cases in which tumor recurred. It implies
that tumor cortical invasion was the cause of peritumoral
edema thus causing greater incidence of the tumor recurrence.
In the current series, it was demonstrated that pial invasion
assessed as lack of clear extrapial cleavage plane has a
signiﬁcant inﬂuence on increased recurrence rate, both in
benign and atypical meningiomas. In our study a similar
correlation was found between progression-free survival andFig. 2 – Kaplan–Meier progression-free survival curve of subpial
benign meningioma. Log rank testing demonstrated a significan
plane of dissection (p = 0.0084).higher amount of peritumoral edema only in atypical
meningiomas. It suggests that larger amount of peritumoral
edema is also associated with other postulated factors such as:
tumoral compression to the adjacent parenchyma causing
cerebral ischemia [27], compression of large veins or sinus vein
producing venous engorgement [27], possible role of a
secretory-excretory phenomenon (VEGF) [28,29] or tumor
drainage vein hypoplasia [30]. Alwernia et al. [31] demonstrat-
ed that independent of histological ﬁnding subpial cleavage
plane is associated with a higher recurrence rate than an
extrapial cleavage plane, probably because meningioma
tendency to invade the pia mater layer results in leaving
small piece of tumor tissue during surgery. Our study versus extrapial surgical cleavage plane in patients with
t difference between the groups favoring extrapial cleavage
Fig. 3 – Kaplan–Meier progression-free survival curve of evidence of pial invasion compared with no evidence of pial invasion
in patients with atypical meningioma. Log rank testing demonstrated a significant difference between the groups favoring no
evidence of pial invasion (p = 0.0104).
Fig. 4 – Kaplan–Meier progression-free survival curve of evidence of bone involvement compared with no evidence of bone
involvement in patients with atypical meningioma. Log rank testing demonstrated a significant difference between the
groups favoring no evidence of bone involvement (p = 0.0033).
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Fig. 5 – Kaplan–Meier progression-free survival curve of evidence of large versus small peritumoral brain edema in patients
with atypical meningioma. Log rank testing demonstrated a significant difference between the groups favoring evidence of
small edema (p = 0.0073).
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 – 1 08conﬁrm that pial invasion affects the recurrence rate in
meningioma and probably these patients may beneﬁt from
postoperative adjuvant irradiation regardless of meningio-
ma histology.
In this study we reported that bone involvement is
associated with increased recurrence rate of atypical menin-
gioma but does not inﬂuence cases of benign tumor. Bone
involvement was considered poor prognostic factor of
atypical meningioma in few studies [32,33]. Meningioma
causes changes in adjacent bone usually in the form of
hyperostosis, which results from direct tumor invasion intoTable 5 – Multivariate analysis (Cox's model). Patient and tumor
for intracranial meningioma.
Variable Regression
coefﬁcient (b)
Standard
error
WHO Grade S0.98 0.41 
Sex 0.47 0.40 
Age 0.05 0.04 
Tumor size 0.33 0.37 
Tumor location 0.51 0.38 
Pial invasion S1.36 0.44 
Bone invasion 0.79 0.42 
Tumor margins 0.39 0.52 
Edema 0.53 0.46 
Tumor calciﬁcation 0.41 0.64 
Resection 0.25 0.38 
Values in bold indicate statistical signiﬁcance.bone [34] and the new bone growth probably results from
periosteal stimulation by tumor invasion [35]. Kallio et al. [36]
reported patients with hyperostotic tumors had a 2.1-fold
relative excess risk of death compared to patients without
hyperostosis. In a study of Jaaskelainen [9] on histologically
benign meningioma tumor attachment to bone was determined
an independent risk factor for recurrence. Gabeau-Lacet et al.
[32] found bone involvement in strong association with
progression and death in atypical meningiomas. These authors
postulated that worse outcomes in patients with bone involve-
ment in the course of atypical meningioma reﬂect more factors associated with recurrence in a patient operated on
p-Value Hazard
ratio
95% CI for hazard
ratio
Lower Upper
0.0158 0.37 0.17 0.83
0.2317 1.61 0.74 3.50
0.1883 0.95 0.89 1.02
0.3723 0.72 0.35 1.49
0.1813 0.60 0.29 1.27
0.0021 0.26 0.11 0.61
0.0578 0.45 0.20 1.03
0.4524 1.48 0.54 4.07
0.2462 0.59 0.24 1.44
0.5197 0.66 0.19 2.33
0.5093 1.29 0.61 2.73
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 – 1 0 9aggressive biological characteristics of these meningiomas
compared to those that do not invade bone and poor outcomes
may result from inadequate treatment of affected bone. Positive
correlation between bone involvement and increased rate of
tumor progression conﬁrms the importance of GTR in the
outcome of patients with atypical meningioma since tumor
invasion into bone may result in leaving a small amount of
tumor and subsequent STR.
We examined the effect of postoperative radiotherapy on
recurrence in patients with atypical meningioma and al-
though there was a trend toward postoperative radiotherapy
having a beneﬁt on tumor recurrence, a log-rank test failed to
demonstrate a statistically signiﬁcant difference. In the
published literature the use of postoperative radiotherapy
in WHO Grade II meningiomas is a matter of debate. Some
authors recommended postoperative radiation therapy for all
cases of atypical meningiomas to improve outcome [2,23,37].
On the other hand Mair et al. [38], Goyal et al. [39] and Jo et al.
[40] concluded that postoperative radiotherapy should be
considered only in case of STR. Modha and Gutin [33]
proposed administration of postoperative radiotherapy after
STR and in cases of demonstrated brain invasion or higher
proliferative index. In contrast, Hardesty et al. [41] did not
demonstrate a signiﬁcant beneﬁt on overall survival or
progression-free survival from adjuvant radiotherapy, even
among patients whose tumors have been subtotally resected.
As the authors implied, additional molecular studies would
help to predict both radiosensitivity and propensity for tumor
recurrence.
5. Conclusions
(1) WHO Grade II type is associated with a higher recurrence
rate than WHO Grade I type.
(2) Pial invasion is associated with an increased rate of
recurrence both in benign and atypical meningiomas. In
atypical meningiomas evidence of bone involvement and
large peritumoral brain edema are associated with tumor
progression.
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